Delivering extraordinary. Empowering ordinary.

We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.

Learn More

Structure-guided Drug Design

We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.

See Our Science

We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE).

View Our Pipeline

Stay up to date with the latest discoveries, events, and reports from BioCryst.

February 25, 2020: BioCryst Appoints Alan G. Levin to Board of Directors
February 20, 2020: BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5
February 18, 2020: FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

VIEW ALL PRESS RELEASES

We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.

JOB OPENINGS